Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-321941


Since December 2019 the world has been facing a newly identified coronavirus named SarsCov-2 which is the causative agent of COVID-19 that produces different symptoms. One of these symptoms is asymptomatic hypoxia, particularly in elderly patients. Despite the absence of signs of respiratory distress, many patients evolve to respiratory failure. The cause of this asymptomatic hypoxia remains unclear;therefore our goal was to evaluate the utility of peripheral oxygen measurements using oximetry in elderly patients with suspected COVID-19 and with no apparent signs of shortness of breath, during 10 consecutive days. Every elderly patient with suspected COVID-19 who sought medical care at one of the 12 Primary Health Unit (PHU) in the South-West area of Campinas, Sao Paulo State was enrolled in the 10-days monitoring report. Each patient had the levels of oxygen saturation (SpO 2 ) monitored by pulse oximeter from the fifth to the tenth days after the onset of symptoms and, when possible, twice a day;1297 patients (pts) were followed during the period from August 2020 to February 2021. A total of 9023 measurements were carried out using a SpO 2 pulse oximeter. 163 (12.5%) cases were referred to the Emergency Room and 37 (3%) had to be hospitalized. The highest frequencies of symptoms occurred during the 6 th and 8 th day and included cough (16.8%), fatigue (12.8%), headache (9.7%), loss of taste and/or smell (6.8%). Among the patients who were hospitalized, 13 died (1%). The asymptomatic hypoxia remains unclear;however, the measurement of SpO 2 levels appears to be a cheap and effective tool to be used as an alert system for further evaluation.

Viruses ; 13(11)2021 10 22.
Article in English | MEDLINE | ID: covidwho-1481018


A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased transmissibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8-3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.

COVID-19 Vaccines , COVID-19/immunology , COVID-19/virology , SARS-CoV-2/classification , SARS-CoV-2/genetics , Vaccination , Adenoviridae , Adult , Aged , Aged, 80 and over , Antibodies, Neutralizing/immunology , Brazil/epidemiology , COVID-19/prevention & control , COVID-19 Serological Testing , Cohort Studies , Disease Outbreaks/statistics & numerical data , Female , Genetic Vectors , Humans , Immunoglobulin G/blood , Male , Middle Aged , RNA, Viral , Vaccines, Inactivated , Whole Genome Sequencing , Young Adult